AL
Therapeutic Areas
Cerus Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INTERCEPT Blood System for Platelets | Pathogen reduction for platelet transfusions | Approved |
| INTERCEPT Blood System for Plasma | Pathogen reduction for plasma transfusions | Approved |
| INTERCEPT Blood System for Cryoprecipitation / INTERCEPT Fibrinogen Complex | Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency | Approved |
| INTERCEPT Blood System for Red Blood Cells | Pathogen reduction for red blood cell transfusions | Phase 3 |
Leadership Team at Cerus
W'
William 'Obi' M. Greenman
President and Chief Executive Officer, Chair of the Board
RJ
Richard J. Benjamin
Chief Medical Officer
LM
Laurence M. Corash
Chief Scientific Officer, Co-founder
VK
Vivek K. Jayaraman
Chief Operating Officer
LL
Lori L. Roll
Vice President of Administration
EH
Eric H. Bjerkholt
Board of Directors, Audit Committee Chair
DA
Dean A. Gregory
Board of Directors, Member
TL
Timothy L. Moore
Board of Directors, Compensation Committee Member
JN
Jami Nachtsheim
Board of Directors, Nominating & Corporate Governance Committee Chair
HS
Hua Shan
Board of Directors, Member